An interventional study of Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System and SAVR in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by JenaValve Technology, Inc.. Recruiting at 40 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 2nd largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 22 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 38th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18–90
Edwards Lifesciences · Sites in United States, Canada
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in United States, Canada
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 1,016 is above the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 226 across the 24 interventional studies, 200 across the 17 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 41 have an industry lead sponsor. The 10 most frequent:
JenaValve Technology, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
JenaValve Technology, Inc. has 6 studies filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Aortic Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608823JenaValve Technology, Inc.ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | 2027-06 |
| NCT04149600Beth Israel Deaconess Medical CenterIdentification of Genetic Causes of Calcific Aortic Valve Disease | 2027-06-30 |
| NCT05459233Institut universitaire de cardiologie et de pneumologie de Québec, University LavalValve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | 2027-09-01 |
| NCT07197736Columbia UniversityDELINEATE-Prospective | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical indication for AVR for native valve predominant AR defined as:
Exclusion Criteria:
Severe Pulmonary Hypertension (pulmonary arterial systolic pressure
Severe (COPD) with
Anatomical exclusion criteria (ANY of the following):
Complex coronary artery disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter Aortic Valve Replacement (TAVR) using the Trilogy THV System
Device: Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System
SAVR using commercially available surgical prosthetic valve
Device: SAVR
Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
SAVR using commercially available surgical prosthetic valves.
All-Cause Mortality
all-cause mortality at 12 months
Time frame: 12 months
All stroke
Number of patients that had stroke
Time frame: 12 months
unplanned cardiac rehospitalization
Number of patients who had unplanned cardiac rehospitalization
Time frame: 12 months
Length of index hospitalization
comparing TAVR length of index hospitalization with SAVR
Time frame: pre-intervention/procedure surgery
Echocardiographic effective orifice area
comparing TAVR Echocardiographic effective orifice area with SAVR
Time frame: 30 days
Moderate or greater patient prosthesis mismatch as measured by echo
comparing TAVR moderate or greater patient prosthesis mismatched with SAVR
Time frame: 30 days or immediately after the intervention/procedure
Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)
comparing change in KCCQ-OS in TAVR with SAVR. the minimum and maximum values vary based on the questionnaire. Higher scores mean better outcome.
Time frame: 30 days
Atrial fibrillation
comparing the onset atrial fibrillation in TAVR with SAVR
Time frame: 30 days
Cardiovascular rehospitalization
comparing the number of cardiovascular rehospitalizations in TAVR with SAVR
Time frame: 30 days
Composite primary endpoints
comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR
Time frame: 30 days
Composite primary endpoints
comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR
Time frame: 1 year
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 30 days
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 6 months
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 1 year
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 2 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 3 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 4 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 5 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 6 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 7 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 8 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 9 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Freedom of Major Adverse Cardiovascular and Cerebrovascular Events
Time frame: 10 years
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JenaValve Technology, Inc.